Arthur Splendoria, MD
Family Medicine · Vero Beach, FLNPI 1346246659
Payments from drug & device makers
Across 140 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$303
- Novo Nordisk$286
- Amgen$285
- Pfizer$273
- Amarin Pharma, Inc.$252
- Merck$130
- plus $980 from 21 others
What the payments were for
- Food & beverage$2,42797%
- Education$331%
- Gifts$502%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 15 | $303 |
| Novo Nordisk | 22 | $286 |
| Amgen | 16 | $285 |
| Pfizer | 16 | $273 |
| Amarin Pharma, Inc. | 14 | $252 |
| Merck | 9 | $130 |
| AstraZeneca | 6 | $126 |
| Daiichi Sankyo Inc. | 4 | $120 |
| Boehringer Ingelheim | 4 | $95 |
| Lilly USA, LLC | 6 | $90 |
| GSK | 4 | $82 |
| AbbVie | 3 | $54 |
| Eisai Inc. | 3 | $50 |
| Tosoh Bioscience, Inc. | 1 | $50 |
| Vivus LLC | 2 | $41 |
| Johnson & Johnson | 2 | $41 |
| Seqirus USA Inc | 2 | $36 |
| Esperion Therapeutics, Inc. | 2 | $36 |
| Bausch Health US, LLC | 1 | $24 |
| Avanir Pharmaceuticals, Inc. | 1 | $21 |
| Abbott | 1 | $19 |
| Vertiflex, Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $12 |
How this compares
$2,510 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 156 | $124,924 |
| JardianceEmpagliflozin | 113 | $99,063 |
| FarxigaDapagliflozin Propanediol | 72 | $66,929 |
| RybelsusSemaglutide | 42 | $57,187 |
| OzempicSemaglutide | 27 | $41,295 |
| XareltoRivaroxaban | 35 | $32,621 |
| TrulicityDulaglutide | 28 | $26,709 |
| MounjaroTirzepatide | 18 | $19,291 |
| JanumetSitagliptin Phos/Metformin Hcl | 27 | $17,200 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $12,658 |
| NexletolBempedoic Acid | 17 | $10,038 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $9,487 |
| MyrbetriqMirabegron | 11 | $5,916 |
| VascepaIcosapent Ethyl | 12 | $5,552 |
| Atorvastatin Calcium | 506 | $5,356 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $273 | $129,748167 claims |
| Boehringer IngelheimJardiance | $95 | $99,063113 claims |
| Novo NordiskRybelsus, Ozempic | $286 | $98,48169 claims |
| AstraZenecaFarxiga | $126 | $66,92972 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $90 | $46,00046 claims |
| Johnson & JohnsonXarelto | $41 | $32,62135 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $82 | $22,14525 claims |
| MerckJanumet | $130 | $17,20027 claims |
| Esperion Therapeutics, Inc.Nexletol | $36 | $10,03817 claims |
| Astellas Pharma US IncMyrbetriq | $12 | $5,91611 claims |
| AbbVieSynthroid | $54 | $5,01458 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Vero Beach
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.